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Abstract: Vesicoureteral reflux [VUR] remains a common problem seen by pediatric providers. Despite a great deal of 
research, the debate regarding how to screen and treat patients reremains tense and controversial. This review seeks to 
summarize the management of VUR with emphasis on recent published findings in the literature and how they contribute 
to this debate. The goals of managing VUR include preventing future febrile urinary tract infections [FUTI], renal 
scarring, reflux nephropathy and hypertension. The topdown approach with upper tract imaging and selective 
vesicocystourethrogram [VCUG] is an emerging alternative approach in the evaluation of children after their first FUTI. 
The elimination of bladder and bowel dysfunction [BBD] is an important management strategy to prevent further FUTIs, 
regardless of treatment choice. Antibiotic prophylaxis is a safe and effective modality to sterilize the urinary tract. 
Endoscopic treatment of VUR is an attractive modality in select patients, although some concerns remain regarding its 
effectiveness and durability as compared to the gold standard of open or laparoscopic ureteroneocystostomy. Lastly, 
further research is required to determine the most effective algorithm to evaluate the pediatric patient after the first febrile 
UTI. 
Keywords: Antibiotic prophylaxis, bladder and bowel dysfunction, dysfunctional voiding, lower urinary tract dysfunction, 
pyelonephritis renal scarring, urinary tract infection, ureteral reimplantation, vesicoureteral reflux. 
1. INTRODUCTION 
 Galen, the ancient anatomist first described the role of the 
vescioureteric valve in the one directional flow of urine in 
the first century AD [1] (Fig. 1). However, it was not until 
Dr. Hutch described a causal relationship between 
vesicoureteral reflux [VUR] and pyelonephritis in the 
paraplegic population that the medical community 
[urologists, in particular] began to devote more attention 
towards the relevance of VUR [2]. Another landmark 
reported by Ransley and Risdon strengthened the 
significance of VUR by finding renal scarring in a porcine 
model with the combination of VUR, elevated intravesical 
pressures and infected urine in the bladder [3]. In 1973, Dr. 
Bailey described “reflux nephropathy” as “the coarse renal 
scarring that results in form of urinary tract infection [UTI] 
in the setting of VUR” [4]. After these seminal reports on 
VUR, VUR has become one of the most studied topics in all 
of pediatric urology. Our current understanding of the 
interplay between UTI, VUR, and renal scarring was heavily 
influenced by the clinical research of Smellie in 1991 that 
pointed out the importance and role of antibiotic prophylaxis 
in promoting kidney health [5]. Unfortunately, despite the 
frequency of VUR within the population and the extensive 
history of study, the proper evaluation and treatment of the 
patient with VUR remains a contentious issue. 
 In the United States, both the American Urological 
Association [AUA] and the American Academy of Pediatrics  
[AAP] have provided guidelines in the hope of helping 
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Fig. (1). Caption: Normal ureterovesical junction and trigone. A. 
Cross-section of the ureterovesical junction. B. Coronal section of 
the ureterovesical junction. From Tanagho EA, Pugh RCB. The 
anatomy and function of the ureterovesical junction. Br J Urol. 
1963; 35:151-65, with permission. 
pediatricians and pediatric urologists provide appropriate 
screening and treatment for patients with both UTIs and 
VUR. In Europe, the European Association of Urology 
[EAU] and the National Institute of Health and Clinical 
Excellence [NICE] have also attempted to lay out guidelines 
on the management of VUR in the pediatric population. In 
the guidelines, bladder and bowel dysfunction [BBD] has 
become more recognized as a major determinant in the 
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potential of future urinary tract infections and resolution of 
VUR [with or without treatment]. This article not only 
recounts current research and guidelines, but also discusses 
the increasing role of BBD and addresses recent landmark 
studies in the screening and management of VUR. 
2. ETIOLOGY 
 The flow of urine from the ureter to the bladder is 
normally one directional across the vesicoureteral junction. 
Normally, VUR does not occur because there is compression 
of the tunneled, submucosal ureter as the bladder fills with 
urine. VUR is a developmental anomaly created by an 
inadequate length of the intravesical submucosal tunnel of 
the ureter in relation to the pressures experienced by the 
patient’s bladder (Fig. 2). Today VUR is classified as either 
primary or secondary VUR. VUR is primary if it is thought 
to be an isolated, fundamental deficiency in the above-
described anatomic ureteral tunnel. Paquin was the first to 
describe the normal anatomical and physiological tunnel’s 
dimensions as 5 [length] to 1 [diameter]. Secondary VUR 
refers to VUR that is due to abnormal bladder dynamics 
and/or elevated voiding pressures. These abnormalities are 
seen with lower urinary tract dysfunction stemming from 
bladder outlet obstruction [posterior urethral valves or 
ureterocele], neurogenic bladder, or dysfunctional voiding. 
In secondary VUR, the vesicoureteral tunnel may or may not 
be of normal length, however, due to elevated intravesical 
voiding pressures, the vesicoureteral tunnel is “insufficient” 
to prevent VUR. Older literature did not appreciate this 
distinction of VUR and it was common to see reports of 
patients with ‘primary reflux’ with a predominance of 
bladder dysfunction. These same reports would describe 
spontaneous resolution of VUR following anticholinergic 
therapy to address the bladder dysfunction [6]. 
3. EPIDEMIOLOGY 
 In 1966, Baker et al. stated that VUR may be present in 
up to 70% of infants who present with a UTI [7]. Within the 
general population, VUR is estimated to be present in 1-2% 
of all children [8]. Interestingly, there are racial and gender 
differences. The incidence of VUR in black children is one 
third to white children [9]. Females are twice as likely as 
males to have VUR in the general population. However, in 
the infant population, VUR is more prevalent in boys. 
Unfortunately, most of our knowledge regarding the 
diagnosis of VUR is confounded by selection bias with the 
population that is screened; those with a previous UTI or 
hydronephrosis [HN] are more likely to be evaluated. Gender 
predispositions of VUR may be related to the prevalence of 
UTI and HN within the general population; hence, a 
significant proportion of VUR may remain undiagnosed. 
 There is a familial relationship of VUR and 
approximately 30% of siblings of index patients will have 
VUR from screening studies. Primary VUR is found with a 
significantly higher prevalence in close relatives of those 
with reflux. Kaefer et al. found that the prevalence of VUR 
was 80% between identical twins and that the prevalence 
was 35% in nonidentical or fraternal twins [10]. Scott et al. 
over a 3-year period studied familial VUR in patients that 
were seen in antenatal clinics [11]. Newborns with parents or 
other family members with definite [cystography] or 
probable VUR were enrolled in the study. Of 211 with 
confirmed family history, there was a prevalence of VUR in 
31% of patients. 
 
Fig. (2). Anatomy of the Ureterovesical Junction. From: Diamond DA, Mattoo TK. Endoscopic treatment of primary vesicoureteral reflux. N 
Engl J Med 2012; 366:1218-26, with permission. 
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3.1. Sibling Screening 
 Today, routine sibling screening for VUR is no longer 
practiced. For those with a brother/sister with VUR, the 
AUA Guidelines would suggest consideration for a voiding 
cystourethrogram [VCUG] only if there is evidence of renal 
scarring on imaging or a history of a significant UTI [12]. 
Similarly, the EAU Guidelines suggest a VCUG if there is 
evidence of renal scarring on ultrasonography or a history of 
urinary tract infection. In older, asymptomatic children, 
screening for VUR is not recommended [13]. In general, 
sibling screening has diminished in practice as we selectively 
evaluate children based on a risk stratification profile rather 
than uniformly screen all siblings. 
4. VUR DIAGNOSIS 
 Traditionally, an acute episode of pyelonephritis 
prompted a diagnostic work-up that included a VCUG, and 
this remains the gold standard imaging test for the diagnosis 
of VUR. The rationale for VCUG testing in the setting of 
pyelonephritis is based on the higher prevalence of VUR 
diagnosed after a significant UTI [often febrile]. A meta-
analysis by Faust et al. determined VUR to be the primary 
risk factor predisposing children to acquired renal cortical 
scarring [approximately 3 fold], possibly by increasing the 
risk of recurrent UTIs [14]. 
 With the widespread adoption of prenatal ultrasound for 
maternal-fetal care, another population now targeted for 
diagnostic evaluation includes those infants with persistent 
abnormalities on a postnatal ultrasound. In these patients, the 
AUA recommends VCUG for those with HN [SFU grade 3 
or 4], hydroureter or an abnormal bladder ultrasound on 
either late prenatal or postnatal ultrasound. Patients with 
lower grade HN are given the options of VCUG or 
observation [12]. The EAU acknowledges that the degree of 
HN is not a reliable indicator of VUR. However, VCUG is 
recommended for those with bilateral high-grade HN, duplex 
kidneys with HN, ureterocele, ureteral dilation or abnormal 
appearing bladders [13]. The 2011 revised AAP Guidelines 
on the management of UTI no longer recommend automatic 
VCUG testing following a UTI. Instead, the AAP 
recommends a VCUG following recurrent febrile UTIs or a 
renal/bladder abnormality on ultrasound showing 
hydronephrosis, hydroureter or evidence of renal scarring 
[14,15]. 
 Once the diagnosis of VUR is established on VCUG, 
VUR is categorized or graded in severity by the degree of 
ureteral dilation on VCUG. The grading system for VUR 
that is globally accepted is based upon the radiologic grading 
system established by the International Reflux Study 
Committee in 1981 [16]. Grade I shows reflux into a non-
dilated ureter; Grade II, into pelvis and calyces without 
dilatation; Grade III, mild to moderate dilatation of ureter, 
renal pelvis and calyces with minimal blunting of fornices; 
Grade IV, moderate ureteral tortuosity and dilatation of 
pelvis and calyces; and Grade V, gross dilatation of ureter, 
pelvis and calyces, loss of papillary impressions and ureteral 
tortuosity. 
 
5. DIAGNOSTIC AND SCREENING PROTOCOLS 
 The challenge in the evaluation and management of VUR 
is primarily due to the lack of consensus on which patients to 
screen and which patients require treatment. As previously 
described, most clinicians use renal and bladder ultrasound 
[RBUS] as a barometer in deciding who should have a 
VCUG. RBUS is an ideal screening tool as it is inexpensive, 
non-invasive and uses no radiation. Unfortunately, some 
studies have found RBUS findings to be hampered by a poor 
sensitivity and negative predictive value for determining 
VUR [17]. In a study comparing ultrasound and VCUG 
imaging within a population of newborns with a family 
history of VUR, there was low sensitivity and a poor 
predictive value for detecting VUR when evaluating prenatal 
and postnatal renal pelvic diameters [18]. The limitations of 
RBUS are highlighted by reports of normal RBUS findings 
in up to 60% of cases of VUR despite missing 50% of renal 
abnormalities noted on dimercaptosuccinic acid renal scan 
[DMSA] [19-21]. Drawbacks to VCUG testing are the 
invasive nature, potential radiation exposure and the risk of 
potential iatrogenic UTI with urethral and bladder 
catheterization. The radiation concern has been lessened with 
limited dosimetry and spot films and the invasive nature has 
been tempered with sedation. Nevertheless, VCUG 
compared to RBUS is clearly provokes more anxiety for 
patients, and families. 
5.1. Top-Down Approach 
 As an alternative to the traditional approach of early 
VCUG testing in the diagnostic evaluation, some clinicians 
advocate a “top-down” approach. The rationale for the top-
down approach is that only VUR that results in 
pyelonephritis is clinically relevant. With the knowledge that 
only pyelonephritis leads to renal scarring, this approach 
employs a DMSA soon following a confirmed, febrile UTI. 
Those with a negative exam would require no further 
evaluation unless recurrent UTI was noted. However, the 
VCUG would be performed upon those with confirmed, 
focal photopenia on DMSA. In a retrospective evaluation of 
the top-down approach, 303 children under 2 years old had a 
DSMA and VCUG performed following their first UTI [22]. 
Despite an 82% rate of FUTIs, VUR was found in only 26%. 
Of those with FUTI and VUR on VCUG, 66% had an 
abnormal DMSA. In this cohort of patients with abnormal 
DMSA scans, the top down approach would have only 
identified 66% of those with VUR and risk of future scarring 
and excluded 40% of the cohort without VUR from a 
VCUG. Of seven patients with dilating, grade III VUR and a 
normal DMSA, all except one had an initial FUTI. 
Furthermore, these same 7 patients with normal DMSA 
scans were found on follow up to have complete resolution 
of VUR [5 patients] or downgraded to grade I VUR [2 
patients]. 
 Tseng et al. conducted a 10-year retrospective review of 
142 children seen at their tertiary care hospital following 
their first UTI [23]. All had DMSA renal scans and VCUG 
performed. Seventy percent of the patients had evidence on  
 
 
The Diagnosis and Treatment of Vesicoureteral Reflux The Open Urology & Nephrology Journal, 2015, Volume 8    99 
DMSA of pyelonephritis, and 1.4% had evidence of scarring 
on DMSA. VCUG found 30% of the patients had VUR. The 
PPV and NPV of abnormalities on DMSA for predicting the 
presence of VUR on subsequent VCUG were 37 and 88%, 
respectively. Five patients with a normal DMSA were noted 
to have VUR on VCUG and they were of low grade.   
 The advantage of the top-down approach is that the 
patients with abnormal DMSA findings would be selectively 
evaluated, as the majority of those with VUR and a febrile 
UTI do not develop renal scarring. By targeting an at risk 
cohort for a VCUG, a segment of children with FUTI would 
be shielded from the morbidity of further screening and 
potential treatment. Unfortunately, increasing use of the 
DMSA scan has limitations. These limitations include 
limited availability of the DMSA isotope, requirement of an 
intravenous line, frequent sedation requirements, radiation 
exposure [albeit small], and higher financial costs. Lastly, 
most patients found to have renal scarring with abnormal 
DMSA scans have a negative VCUG and the persistence of 
renal parenchymal lesions is independent of VUR [24]. 
Whether these lesions appeared prior to the presenting UTI 
and whether they necessitate antibiotic prophylaxis remains 
uncertain. 
 Interestingly, DMSA scan abnormalities in conjunction 
with high grade VUR [e.g. grades 3-5] are associated with a 
greater chance for breakthrough UTI [60%] despite antibiotic 
prophylaxis when compared to those with a normal DMSA 
and a similar VUR grade [8%] [25]. Furthermore, only 5% 
of those with an abnormal DMSA showed VUR 
improvement compared to 46% that resolved in the normal 
DMSA group. When referencing the AUA guidelines, 
DMSA imaging is recommended in the setting of an 
abnormal renal ultrasound that suggests scarring or an 
elevated serum keratinize [12]. The EAU Guidelines 
mention the alternative top-down approach and describe the 
potential to miss 5-27% cases of VUR, with questionable 
significance [13]. 
6. BLADDER AND BOWEL DYSFUNCTION 
6.1. VUR, UTIs, and BBD 
 There is a known relationship and co-morbidity between 
VUR and bladder and bowel dysfunction [BBD]. In 1979, 
Koff et al. studied 53 neurologically intact children with UTI 
and BBD and found that 50% had VUR [26]. Recently, this 
relationship has been further elucidated by the Swedish 
reflux trial in children where they found a total of 20% of 
patients enrolled with high grade reflux had bladder 
dysfunction characterized by a high bladder capacity and 
incomplete bladder emptying associated with an increased 
post-void residual [27]. Dilating reflux directly correlated 
with bladder dysfunction and successful treatment of bladder 
dysfunction was associated with improvement of reflux 
grade. Furthermore, renal damage at study entry and follow-
up was significantly associated with bladder dysfunction at 2 
years. 
 The latest AUA VUR guidelines recognize this 
concomitant relationship between VUR, UTIs, and BBD 
[12]. BBD has a negative correlation with the spontaneous 
VUR resolution rate and the success rate following 
endoscopic surgery (Fig. 3). Additionally, there is a higher 
incidence of postoperative UTI in those children with both 
VUR and BBD [12]. Due to this comorbidity, the AUA 
recommends screening for symptoms indicative of BBD 
upon initial evaluation. These symptoms include urinary 
frequency, urgency, prolonged voiding intervals, daytime 
wetting, perineal/penile pain, holding maneuvers and 
constipation/encopresis. The guidelines recommend 
treatment of BBD prior to any surgical treatment of VUR. 
Lastly, continuous antibiotic prophylaxis [CAP] is 
recommended for those with concomitant BBD and VUR 
due to an increased risk of UTI. The EAU guidelines also 
acknowledge the association between lower urinary tract 
dysfunction [LUTD] and VUR [13]. They also state a video-
urodynamic study may be warranted if a child with LUTD 
and a history of FUTIs is refractory to standard bladder 
urotherapy [13]. 
 In contrast to endoscopic correction, open ureteral 
reimplantation can be quite successful in the treatment of 
VUR in children, regardless of the presence of BBD [28]. 
This is attributed to the more durable continence mechanism 
created by ureteral reimplantation. The continence 
mechanism for endoscopic ureteral injection relies on 
principles of Poiseuille’s Law by narrowing the radius of the 
ureteral lumen with a bulking agent and thus increases 
resistance of retrograde urine flow. This increased resistance, 
though, is more susceptible to persistence of VUR in the 
setting high pressure voiding with BBD. In contrast, the 
continence mechanism established by ureteral reimplantation 
is based on a flap-valve mechanism which allows coaptation 
of the tunneled ureteral segment during bladder filling and is 
significantly more reliable in treatment of VUR for those 
with BBD. 
 A critical driving force in the management of VUR is the 
presence of UTI and in particular FUTI. With BBD, there is 
a significant elevated risk and incidence of UTIs. The 
association of UTIs with BBD is due to several 
characteristics of the lower urinary tract with BBD that 
provides an ideal environment for the propagation of 
uropathic bacteria. Children with BBD often void 
infrequently or have incomplete emptying which results in a 
prolonged dwelling time of urine and incubation time for 
bacterial growth. 
6.2. BBD Assessment and Management 
 After identifying LUTD, it is recommended to screen for 
the presence of concomitant bowel dysfunction given their 
frequent interdependence. The coexistence of bladder and 
bowel dysfunction is termed BBD [29] and the importance of 
BBD is that the physiologic regulation of the bladder and 
bowel are shared and thus dysfunction in one organ system is 
seen in the other organ. Multiple studies have demonstrated 
that treatment of bowel dysfunction first can lead to 
resolution of bladder dysfunction [and a significantly lower 
rate of UTI], and vice versa [30-32]. The assessment of BBD 
should consist of a thorough history, physical exam, and 
several noninvasive studies. Recommended testing for BBD 
includes urinalysis, +/- urine culture, elimination diaries, 
symptom questionnaires, uroflowmetry with or without 
EMG and pelvic ultrasound to evaluate the functional and 
anatomical characteristics of the bladder and bowel [30, 34]. 
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 Management of BBD initially consists of behavioral 
modification [termed standard urotherapy] that entails 
education regarding the anatomy and function of the bladder, 
bowel and pelvic floor musculature. Details regarding timed 
voiding, proper voiding posture, double voiding, and pelvic 
floor relaxation exercises are all mentioned in the literature 
as valid treatments of LUTD [33]. More innovative and 
interactive treatments are reserved for children that do not 
respond to standard urotherapy [34]. A recent study by Ladi-
Seyedian et al. assessed the efficacy of animated 
biofeedback and pelvic floor muscle exercises in children 
with non-neuropathic underactive bladder [35]. In terms of 
UTI relapse rates, postvoid residual volume, voiding time, 
and maximum urine flowrate, patients receiving biofeedback 
therapy fared significantly better than the controls after six 
months of treatment. Pharmacologic therapy [e.g. alpha 
blockers and Botulinum-A toxin] is also selectively used to 
improve bladder emptying despite their off-label and/or 
investigational nature [36-38]. Finally, intermittent urethral 
catheterization of the bladder is a rare requirement to empty 
the bladder in patients with refractory BBD or LUTD and 
recurrent UTIs. 
7. TREATMENT OPTIONS 
7.1. Continuous Antibiotic Prophylaxis [CAP] 
 For years, CAP’s efficacy has been questioned because 
of its potential risks [selecting resistant organisms, Stevens-
Johnson syndrome] and uncertain benefit [39-41]. Later 
studies provided clear evidence of the efficacy of CAP as 
compared to observation. The most notable examples 
included Craig et al. with the PRIVENT study and the 
Swedish reflux trial in children [42,43]. These studies, 
however, demonstrated a small benefit from CAP. Some 
argued that the results were statistically, but not clinically 
significant. Others argued that these studies only included a 
subset of patients with high grade VUR, and were therefore 
not generalizable to whole VUR population. The recently 
published RIVUR [Randomized Intervention for Children  
 
with Vesico-Ureteral Reflux] trial is now the largest, 
randomized, placebo-controlled, double-blinded, multicenter 
study comparing CAP [trimethoprim/sulfamethoxazole] to 
placebo [44]. The RIVUR trial addressed limitations in the 
PRIVENT and Swedish reflux trial studies by using a 
placebo control, examining a large sample size of children 
with VUR and employing strict UTI criteria [catheterized 
specimens for all non-toilet-trained patients enrolled]. The 
RIVUR study included 607 patients aged 2-72 months with 
grade I-IV VUR and a first or second symptomatic UTI. The 
majority of patients were female [92%] and 86% of the 
patients had an index FUTI including 56% of the 126 toilet-
trained children with BBD. Although no significant 
difference was seen in the incidence of renal scarring, the 
RIVUR study significantly found a 50% relative decrease in 
the incidence of UTIs in those treated with CAP. There was 
no significant difference seen in the study cohorts’ resistance 
patterns of fecal Escherichia coli. However, the first 
symptomatic UTI with resistant E. coli was statistically more 
likely to occur among those on prophylaxis [63% vs 19% of 
placebo]. Interestingly, the benefit of CAP was most 
pronounced in those with bladder dysfunction as well as 
those who initially presented with a febrile UTI. 
 In the AUA VUR Clinical Guidelines, the benefit of CAP 
was based on the recommended use of screening criteria to 
determine a risk profile of future UTIs [12]. High-risk 
groups who would benefit from CAP included those <1years 
of age, dilating VUR [grades 3-5] and/or a history of febrile 
UTI. For those > 1year of age, CAP is recommended in 
those with BBD. Otherwise, CAP is considered optional for 
those >1 year of age. The EAU VUR guidelines suggest that 
regardless of the grade of reflux or presence of renal scars, 
all patients diagnosed at age < 1 year can be treated initially 
with CAP [13]. Definitive surgical or endoscopic correction 
is preferred for those with frequent breakthrough infections. 
In all children presenting at age 1-5 years, CAP is the 
preferred, initial option. However, those with lower grades of 
reflux and no symptoms are considered potential candidates 
for surveillance without CAP. 
 
Fig. (3). Forest plots depicting the negative influence of BBD on the resolution rate of VUR. Patients with BBD have a lower resolution rate 
(a) compared to patients without BBD (b). Elder JS, Diaz M. Vesicoureteral reflux—the role of bladder and bowel dysfunction. Nat Rev 
Urol. doi:10.1038/nrurol.2013.221, with permission. 
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7.2. Surgery 
 The recommendation for surgical treatment is a shared-
decision-making process involving the parents/guardians and 
physician. The decision is influenced by multiple factors 
including the risk-benefit of intervention, presence of 
breakthrough UTIs and also the anxiety from VCUG testing 
with persistent VUR. 
 Endoscopic therapy is an attractive, minimally invasive, 
outpatient, surgical option in the treatment of VUR. The 
injection of polytetrafluoroetheylene [Teflon] to treat VUR 
was used in the 1980’s and 1990’s until reports of safety 
concerns and adverse reactions associated with Teflon 
migration into other organs negated its usage. Endoscopic 
therapy has re-emerged in the surgical treatment for VUR 
since the Federal Drug Administration approved 
dextranomer hyaluronic acid copolymer [Deflux®] in 2001 
for endoscopic correction of grades II-IV VUR [45, 46]. The 
success rate of endoscopic treatment is approximately 60-
90% and is more dependent and influenced by the grade of 
VUR and the absence of BBD. Modification of endoscopic 
techniques by using multiple submucosal injection sites at 
the ureteral orifice has been reported to improve success 
rates [47, 48]. A meta-analysis by Elder et al., however, 
suggests the most significant prognostic factor in the success 
of endoscopic treatment is the pre-operative VUR grade, not 
the particular technique [49]. 
 Open neoureterocystotomy or ureteral reimplantation is 
the “gold standard” for surgical correction of VUR. The 
success rate of open ureteral reimplantation is approximately 
95% regardless of VUR grade or presence of BBD. Ureteral 
reimplantation corrects an inadequate ureteral tunnel length 
by establishing a flap-valve mechanism that allows passive 
compression of the submucosal ureter during bladder filling. 
The key of surgical characteristic in the construction of the 
reimplanted ureter is establishing a 5:1 ratio in the tunneled 
length-to-ureteral diameter [50]. There are multiple surgical 
variations of open ureteral reimplantation that involve 
intravesical [IV], extravesical [EV] or combined intra- and 
extravesical dissections [51-56]. 
 The first of the IV approaches is the Politano-Leadbetter 
reimplant. Refluxing ureters are commonly located too 
lateral within the bladder and this approach involves the 
creation of a neo-hiatus insertion site into the posterior 
bladder wall superior and medial to the original hiatus [51]. 
The ureter is passed from the new hiatus through a newly 
created, submucosal tunnel toward the bladder neck. The 
Glenn-Anderson technique involves the same IV 
mobilization and ureteral tunneling found in the Politano-
Leadbetter technique, however, there is no translocation to a 
new hiatus and the original hiatus is maintained [52]. The 
decision-making for a Glenn-Anderson technique is 
dependent upon the anatomy of the patient’s trigonal and 
bladder anatomy and whether the ureter is located too 
inferiorly preventing a 5:1 length:diameter ratio for the 
tunneled advancement. 
 The cross-trigonal, Cohen ureteral reimplant is an IV 
mobilization of the ureter that maintains the original 
insertion hiatus into the bladder wall [53]. Unlike the Glenn-
Anderson technique, the ureter is reimplanted across the 
trigone toward the contralateral ureter. This surgical 
technique is particularly advantageous in the creation of a 
long tunnel for reimplanted dilated ureters. Some argue, 
however, that this technique affects the anatomy by making 
endoscopic access to the ureters more difficult if needed in 
the future [e.g. for urolithiasis], but this does not seem to be 
an issue longitudinally. 
 Both Lich and Gregoir simultaneously developed the EV 
technique of ureteral reimplantation [54]. The technique 
involves EV dissection of the ureter toward the ureteral 
orifice, followed by an incision through the seromuscular 
layer but not through the mucosal layer to create a bed for 
the EV ureter, followed by a closure of the detrusor muscle 
defect upon the ureter. This technique was originally rejected 
in the United States amid fears of poor results, but this 
changed over the last few decades and the longitudinal 
results are equivocal to IV techniques [55]. A notable 
morbidity resulting from EV ureteral reimplantation is the 
development of transient urinary retention in approximately 
16% of patients. This is attributed to a transient neuropraxia 
[56,57]. Fortunately, the incidence of urinary retention is 
significantly reduced in patients undergoing unilateral EV 
ureteral reimplantation. Patients with unilateral VUR are 
thus an ideal selection group for EV reimplantation. 
Persistent advocates of bilateral, EV ureteral reimplantation 
report low incidence of urinary retention with modifications 
of the surgical dissection including limited ureteral 
dissection and mobilization, no ligation of the obliterated 
umbilical artery, no dissection in proximity to the obliterated 
umbilical artery and use of a low-coagulation-current needle-
tip Bovie [58]. 
 Laparoscopic iterations of these EV techniques have been 
subsequently developed in the hope of achieving a shorter 
period of convalescence and less postoperative pain [59-61]. 
Laparoscopic IV iterations of the open, Cohen ureteral 
reimplantation approach have also been developed [62-64]. 
Another recent laparoscopic variation includes robot-assisted 
laparoscopy using the Da Vinci platform for EV, 
laparoscopic ureteral reimplantation [65]. 
 The 2010 AUA Clinical Guidelines consider surgical 
intervention as an “option” in the management of VUR [12]. 
The International Reflux Study in Children compared 
children with <11 years of age with dilating VUR randomly 
assigned to surgical intervention or CAP. This study showed 
no difference in “urographic" renal scars, UTI recurrence 
rate, or renal growth. However, there was an increase in 
febrile UTIs in the CAP group found after ten years of 
follow up [66]. Subsequently, they recommend that “patients 
receiving CAP with a febrile breakthrough-UTI be 
considered for open surgical ureteral reimplantation or 
endoscopic injection, with curative intent.” 
CONCLUSION 
 The evaluation and management of VUR has changed 
significantly over the last two decades. The increased 
knowledge of the natural history of VUR and the 
identification of high-risk groups has tailored clinical 
decision-making and testing for VUR. RBUS and DMSA 
imaging are now frequently used in lieu of an immediate 
VCUG. We know that UTI is an important driving factor in 
the management of VUR and that infection control for UTI 
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supersedes the significance of VUR. Another significant 
concept that is better understood in the management of VUR 
is the role of BBD. BBD is a significant risk factor for the 
prevalence of UTIs and development of secondary VUR. 
The evaluation for BBD in toilet-trained patients with VUR 
and UTIs should routinely be performed, as successful BBD 
management promotes downgrading or elimination of VUR. 
 New findings from the RIVUR trial show that CAP is 
associated with a substantially reduced risk of UTI 
recurrence among children with VUR but not of renal 
scarring. Lastly, surgical correction of VUR in selected 
patients remains a definitive treatment choice and there is a 
wide array of surgical techniques that can be tailored for the 
treatment of VUR. 
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FUTI = Febrile urinary tract infection 
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IV = Intravesical 
LUTD = Lower urinary tract dysfunction 
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UTI = Urinary tract infection 
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